Evidence map›Paper›PMID 16751797›Full record

ReviewBritish journal of pharmacology2006

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Paul Abrams, Karl-Erik Andersson, Jerry J Buccafusco, Christopher Chapple, William Chet de Groat, Alison D Fryer, Gary Kay, Alan Laties, Neil M Nathanson, Pankaj Jay Pasricha and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 8 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 8 syntheses or guidelines pooled it, 629 citations in OpenAlex.

  1. Effect ofFrontiers in pharmacology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. A phase II dose-ranging study of mirabegron in patients with overactive bladder.International urogynecology journal · 2013 · on this map
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Paul AbramsBristol Urological Institute, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB. paul_abrams@bui.ac.uk
Karl-Erik Andersson
Jerry J Buccafusco
Christopher Chapple
William Chet de Groat
Alison D Fryer
Gary Kay
Alan Laties
Neil M Nathanson
Pankaj Jay Pasricha
Alan J Wein
Lund University · SERoyal Hallamshire Hospital · GBSouthmead Hospital · GBUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. The effectiveness of antimuscarinic agents in the treatment of the overactive bladder (OAB) syndrome is thought to arise through blockade of bladder muscarinic receptors located on detrusor smooth muscle cells, as well as on nondetrusor structures. 2. Muscarinic M3 receptors are primarily responsible for detrusor contraction. Limited evidence exists to suggest that M2 receptors may have a role in mediating indirect contractions and/or inhibition of detrusor relaxation. In addition, there is evidence that muscarinic receptors located in the urothelium/suburothelium and on afferent nerves may contribute to the pathophysiology of OAB. Blockade of these receptors may also contribute to the clinical efficacy of antimuscarinic agents. 3. Although the role of muscarinic receptors in the bladder, other than M3 receptors, remains unclear, their role in other body systems is becoming increasingly well established, with emerging evidence supporting a wide range of diverse functions. Blockade of these functions by muscarinic receptor antagonists can lead to similarly diverse adverse effects associated with antimuscarinic treatment, with the range of effects observed varying according to the different receptor subtypes affected. 4. This review explores the evolving understanding of muscarinic receptor functions throughout the body, with particular focus on the bladder, gastrointestinal tract, eye, heart, brain and salivary glands, and the implications for drugs used to treat OAB. The key factors that might determine the ideal antimuscarinic drug for treatment of OAB are also discussed. Further research is needed to show whether the M3 selective receptor antagonists have any advantage over less selective drugs, in leading to fewer adverse events.

Indexed as

AnimalsDose-Response Relationship, DrugHumansModels, BiologicalMuscarinic AntagonistsReceptor, Muscarinic M3Receptors, MuscarinicTissue DistributionUrinary Bladder, OveractiveMuscarinic AntagonistsReceptor, Muscarinic M3Receptors, Muscarinic

Identifiers

PMID16751797
PMCPMC1751864
OpenAlexW2105391780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.